Childhood growth hormone treatment in women with Turner syndrome - benefits and adverse effects

Irzyniec, Tomasz; Jeż, Wacław; Lepska, Katarzyna; Maciejewska-Paszek, Izabela; Frelich, Jakub

doi:10.1038/s41598-019-52332-0

Cited by 19 publications

(27 citation statements)

References 31 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, they also had low thrombocyte counts, a greater prevalence of retrognatism, nail anomalies and elevated creatinine levels, especially when the GH treatment was delayed or prolonged. They concluded that GH treatment in children with TS has benefits in adulthood but adverse effects may occur, especially in girls with treatment that is delayed or is too long [63].…”

Section: Ghd In the Context Of Genetic Disordersmentioning

confidence: 99%

Impact of Pituitary Autoimmunity and Genetic Disorders on Growth Hormone Deficiency in Children and Adults

Bellastella

Maiorino

Longo

et al. 2020

IJMS

View full text Add to dashboard Cite

Growth hormone (GH), mostly through its peripheral mediator, the insulin-like growth factor 1(IGF1), in addition to carrying out its fundamental action to promote linear bone growth, plays an important role throughout life in the regulation of intermediate metabolism, trophism and function of various organs, especially the cardiovascular, muscular and skeletal systems. Therefore, if a prepubertal GH secretory deficiency (GHD) is responsible for short stature, then a deficiency in adulthood identifies a nosographic picture classified as adult GHD syndrome, which is characterized by heart, muscle, bone, metabolic and psychic abnormalities. A GHD may occur in patients with pituitary autoimmunity; moreover, GHD may also be one of the features of some genetic syndromes in association with other neurological, somatic and immune alterations. This review will discuss the impact of pituitary autoimmunity on GHD and the occurrence of GHD in the context of some genetic disorders. Moreover, we will discuss some genetic alterations that cause GH and IGF-1 insensitivity and the arguments in favor and against the influence of GH/IGF-1 on longevity and cancer in the light of the papers on these issues that so far appear in the literature.

show abstract

Section: Ghd In the Context Of Genetic Disordersmentioning

confidence: 99%

Impact of Pituitary Autoimmunity and Genetic Disorders on Growth Hormone Deficiency in Children and Adults

Bellastella

Maiorino

Longo

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…The international guidelines (4) recommend initiation of hormone replacement therapy (HRT) between 11-12 years of age. Soriano-Guillen et al (18) report of age at start of HRT between 14.6 and 16 years of age, while Irzyniec et al (19) start HRT between 8 and 14 years of age. Published Bulgarian data from Stefanova et al for the treatment of TS children documented starting of HRT at the age of 13.5-15 years.…”

Section: Discussionmentioning

confidence: 99%

Treatment with recombinant growth hormone in children with Turner syndrome: a study from a tertiary university center

Rankova

Iotova

Mladenov

et al. 2021

SSM

View full text Add to dashboard Cite

INTRODUCTION: Turner syndrome (TS) is a rare disease with typical phenotype manifestations and short stature. Part of the therapy in TS patients is the recombinant human growth hormone (rhGH) that leads to improved height velocity and final height. AIM:The aim of the current study is to summarize the results of the diagnosis and treatment with rhGH of the TS patients followed up at a tertiary university center from 2011 to 2020. PATIENTS AND METHODS:The study design is a retrospective cohort evaluation. All study participants had at least one full year of observation at the center. A total of 28 children with genetically confirmed TS or TS variation karyotype, aged between 2 and 18 years, 92.9 % of whom were girls, participated in the study. RESULTS:The mean age at diagnosis was 9.6±3.7 years. Therapy with rhGH was started at 9.27±3.4 years in 22 (78.5%) of them with a mean rhGH dose of 0.035±0.006 mg/kg/d, which led to height gain of 8.0±1.3 cm for the first year. With a similar rhGH dose for the 2 nd year of treatment (0.033±0.007 mg/kg/d), height velocity of 6.8±1.1 cm was achieved (p<0.005). A positive change in SDS height was observed for the first year of therapy (-2.75±1.2 vs. -2.27±1.2, p=0.005). SDS IGF-1 before and after one treatment year increased significantly (-0.74±1.1 vs.1.57±1.4, p=0.001), without exceeding 2.0 SD. CONCLUSION:The achieved growth in the presented TS cohort is suboptimal though consistent with the international guidelines for treatment of TS, and could help optimize future treatment approach to TS patients in our center.

show abstract

“…Furthermore, earlier and proper treatment with GH at higher dose can improve growth better [9]. Childhood GH treatment also has bene cial effect on lipid pro le and cardiovascular diseases in women with TS [10].…”

Section: Introductionmentioning

confidence: 99%

Recombinant Growth Hormone Therapy in Children With Turner’s Syndrome in Korea: A Phase III Randomized Trial

Kim¹,

Kim²,

Suh³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Short stature is the most consistent characteristic feature of Turner syndrome (TS). To improve final heights of children with TS effectively, it is important to provide them with early and appropriate treatment using growth hormone (GH). The objective of this study was to assess the efficacy and safety of a new recombinant human GH, Growtropin®-II (DA-3002, Dong-A ST Co., Ltd) in comparison with a comparator (Genotropin®, Pfizer Inc.) for Korean children with TS. Methods This open-label, active-controlled, parallel-group, randomized controlled phase III trial was conducted at 11 hospitals in Korea. Eligible patients (n = 58) were randomized to two groups: 1) DA-3002 group (administrated with DA-3002 at 0.14 IU /kg/day); and 2) comparator group (administrated with the comparator at 0.14 IU /kg/day). Results The change from baseline in annualized height velocity (HV) after a 52-week treatment was 4.15 ± 0.30 cm/year in the DA-3002 group and 4.34 ± 0.29 cm/year in the comparator group. The lower bound of 95% two-sided confidence interval for group difference in the change of annualized HV (-1.02) satisfied the non-inferiority margin (-1.5). The change in height standard deviation score (HtSDS) at 52-week was 0.70 ± 0.23 for the DA-3002 group and 0.66 ± 0.39 for the comparator group, showing no significant (p = 0.685) difference between the two groups. Skeletal maturity defined as a change in bone age or a change in chronological age between the two groups was not significantly different (1.25 ± 0.58 for the DA-3002 group and 1.47 ± 0.45 for the comparator group, p = 0.134). Changes of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) after 52 weeks of treatment did not differ significantly between the two groups (p = 0.565 and p = 0.388, respectively) either. Adverse events were not significant in either group. Conclusions This study demonstrates that the efficacy and safety of GH treatment with DA-3002 in children with TS are comparable with those of the comparator. Thus, treatment with DA-3002 can be used to improve their growth. DA-3002 is also well tolerated in children with TS. Trial registration: The study was registered at ClinicalTrials.gov. ClinicalTrials.gov identifier: NCT01813630 (19/03/2013)

show abstract

Childhood growth hormone treatment in women with Turner syndrome - benefits and adverse effects

Cited by 19 publications

References 31 publications

Impact of Pituitary Autoimmunity and Genetic Disorders on Growth Hormone Deficiency in Children and Adults

Impact of Pituitary Autoimmunity and Genetic Disorders on Growth Hormone Deficiency in Children and Adults

Treatment with recombinant growth hormone in children with Turner syndrome: a study from a tertiary university center

Recombinant Growth Hormone Therapy in Children With Turner’s Syndrome in Korea: A Phase III Randomized Trial

Contact Info

Product

Resources

About